Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.46 |
| ▸ | MARS1 | P56192 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 5/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583003 | 0.89 | DPP4 (0.42) | P2RX7MARS1DPP4HRH1DPP8 | |
| SCHEMBL3096548 | 0.89 | CDK9 (0.42) | P2RX7ADRA1DALDH1A1 | |
| SCHEMBL3079559 | 0.88 | DPP4 (0.51) | DPP4DPP8DPP9CYP3A4KCNH2 | |
| SCHEMBL3606001 | 0.87 | DPP4 (0.44) | MARS1DPP4HRH1DPP8DPP9 | |
| SCHEMBL3091375 | 0.86 | DPP4 (0.47) | DPP4DPP8CYP3A4KCNH2 | |
| SCHEMBL3592478 | 0.83 | P2RX7 (0.44) | P2RX7MARS1DPP4ADRA1DHRH1 | |
| SCHEMBL3084292 | 0.82 | CNR1 (0.46) | DPP4 | |
| SCHEMBL3595249 | 0.82 | DPP4 (0.47) | DPP4DPP8DPP9CYP3A4 | |
| SCHEMBL3091436 | 0.81 | DPP4 (0.46) | DPP4DPP8DPP9CYP3A4KCNH2 | |
| SCHEMBL3595741 | 0.81 | DPP4 (0.44) | DPP4DPP8DPP9CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | claimed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| EP-2007734-A1 | ENZYME INHIBITORS | Probiodrug AG (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007116092-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116092-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244177-A1 | ENZYME INHIBITORS | ACHE, BACE1, MAOA | P2RX7 2321/4885MARS1 1672/4885DPP4 147/4885 |
| US-20100234397-A1 | ENZYME INHIBITORS | ACHE, MAOA, BACE1 | P2RX7 2025/4885MARS1 1786/4885DPP4 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.